Arie Belldegrun - Jan 25, 2024 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
Director
Signature
/s/Earl Douglas, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Jan 25, 2024
Transactions value $
$0
Form type
4
Date filed
1/31/2024, 05:46 PM
Previous filing
Sep 8, 2023
Next filing
May 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +212K +12.81% $0.00 1.87M Jan 25, 2024 Direct
holding ALLO Common Stock 1.8M Jan 25, 2024 See footnote F1
holding ALLO Common Stock 195K Jan 25, 2024 See footnote F2
holding ALLO Common Stock 4.71M Jan 25, 2024 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +749K $0.00 749K Jan 25, 2024 Common Stock 749K $3.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F2 The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun
F3 The securities are held in the name of Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary
F4 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.